Skip to main content

Table 1 Baseline characteristics of included studies

From: Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis

Authors (Year) Language Populations Study design Study period NOS Categories No. samples Mean age (Years) Genders (Male/Female) NIT (Yes/No) Stages
CP features Prognosis Total PE NE
Boone et al. (2008) [38] English Netherland ROS 1989–2006 7 105 26 79 62.0 56/49 None I-IV
Chen et al. (2010) [39] Chinese China mainland ROS 2006–2007 7 62 33 29 NI NI None NI
Chuang et al. (2015) [40] English Taiwan ROS NI 8 75 39 36 57.0 72/3 54/21 I-IV
Hirashima et al. (2010) [41] English Japan ROS 1996–2006 9 143 71 72 63.8 126/17 None I-III
Hou et al. (2014) [42] English China mainland ROS NI 7 35 22 13 61.3 16/19 None I-IV
Kim et al. (2013) [43] English Korea ROS 1995–2008 8 165 74 91 NI 159/6 None I-IV
Li et al. (2012) [44] English Taiwan ROS 1999–2009 9 77 44 33 52.0 75/2 All received I-III
Li et al. (2015) [45] English Taiwan ROS NI 8 105 59 46 54.0 103/2 None I-IV
Lu et al. (2015) [46] English China mainland ROS 2010–2012 8 148 94 54 59.0 114/34 None I-III
  1. CP clinicopathological, CSS cancer-specific survival, DDE demographic data extrapolated, DFS disease-free survival, HR hazard ratio, IHC immunohistochemistry, M multivariate, NE negative expression, NI no information, NIT neo-adjuvant induction therapy, NOS Newcastle-Ottawa Scale, OR odds ratio, OS overall survival, PE positive expression, ROS retrospective observational study, U univariate